Drugs / XZB-0004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05772455 | Mar 2023 → Jun 2025 overdue | non-small cell lung carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05740917 | Feb 2023 | acute myeloid leukemia, myelodysplastic syndrome | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XZB-0004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05772455 ↗ |
| Action | Inhibit | “inhibitor of receptor tyrosine kinase AXL” NCT05772455 ↗ |
| Modality | Small molecule | “small molecule inhibitor” NCT05772455 ↗ |
| Route | Oral | “XZB-0004 orally Twice daily of every 28-day cycle” NCT05740917 ↗ |
| Target | AXL | “inhibitor of receptor tyrosine kinase AXL” NCT05772455 ↗ |